Peel Hunt Reiterates Buy Rating for Oxford Biomedica (LON:OXB)

Key Points

• Oxford Biomedica's stock received a **"buy" rating** from Peel Hunt, with a target price of GBX 451 ($5.99), indicating a potential downside of **1.64%** from its current price.
• JPMorgan Chase has downgraded its price objective for the company's shares from GBX 490 ($6.51) to GBX **400 ($5.31)**, setting a **"neutral" rating**.
• Insider Heather Preston purchased **11,389 shares** at an average price of GBX 324 ($4.30), demonstrating insider confidence as corporate insiders now hold **21.17%** of the company's stock.

Oxford Biomedica (LON:OXB - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Peel Hunt in a research note issued to investors on Friday, August 1st, Marketbeat Ratings reports. They currently have a GBX 451 ($6.07) price objective on the biopharmaceutical company's stock. Peel Hunt's price objective would suggest a potential upside of 2.39% from the company's current price.

Separately, JPMorgan Chase & Co. cut their price target on shares of Oxford Biomedica from GBX 490 ($6.59) to GBX 400 ($5.38) and set a "neutral" rating on the stock in a report on Tuesday, July 15th.

Oxford Biomedica Stock Down 0.5%

Shares of OXB traded down GBX 2.04 ($0.03) during mid-day trading on Friday, hitting GBX 440.47 ($5.92). 80,005 shares of the company traded hands, compared to its average volume of 225,913. The business has a 50 day moving average of GBX 358.80 and a 200 day moving average of GBX 335.48. The company has a market capitalization of £468.22 million, a PE ratio of -3.27 and a beta of 1.09. Oxford Biomedica has a 1-year low of GBX 232.50 ($3.13) and a 1-year high of GBX 471.50 ($6.34). The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48.

Insiders Place Their Bets

In related news, insider Heather Preston acquired 11,389 shares of the stock in a transaction on Tuesday, June 17th. The shares were acquired at an average price of GBX 324 ($4.36) per share, for a total transaction of £36,900.36 ($49,623.94). Company insiders own 21.17% of the company's stock.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.